Price
$1.05
Increased by +3.96%
Dollar volume (20D)
995.32 K
ADR%
8.72
Earnings report date
Aug 7, 2024
Shares float
987.10 M
Shares short
3.52 M [0.36%]
Shares outstanding
255.56 M
Market cap
258.12 M
Beta
2.44
Price/earnings
N/A
20D range
1.01 1.34
50D range
0.87 1.65
200D range
0.42 2.05

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom.

It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.

The company has strategic collaboration and license agreement with Genentech, Inc. and F.

Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center.

Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
May 15, 24 0.00
Decreased by -100.00%
-0.10
Increased by +100.00%
Mar 26, 24 -0.24
Decreased by -33.33%
-0.10
Decreased by -140.00%
Nov 8, 23 -0.20
Increased by +16.67%
-0.12
Decreased by -66.67%
Aug 9, 23 -0.23
Increased by +17.86%
-0.13
Decreased by -76.92%
May 12, 23 0.01
Increased by +103.33%
-0.15
Increased by +106.67%
Mar 6, 23 -0.18
Increased by +25.00%
-0.25
Increased by +28.00%
Nov 8, 22 -0.24
Increased by +20.00%
-0.24
Aug 4, 22 -0.28
Decreased by -16.67%
-0.25
Decreased by -12.00%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Dec 31, 23 233.01 K
Decreased by -97.89%
-48.33 M
Decreased by -65.24%
Decreased by -20.74 K%
Decreased by -7.72 K%
Sep 30, 23 7.32 M
Increased by +4.45%
-45.60 M
Decreased by -10.09%
Decreased by -623.05%
Decreased by -5.40%
Jun 30, 23 5.13 M
Decreased by -7.37%
-21.39 M
Increased by +51.96%
Decreased by -416.94%
Increased by +48.14%
Mar 31, 23 47.60 M
Increased by +1.23 K%
1.04 M
Increased by +102.06%
Increased by +2.18%
Increased by +100.15%
Dec 31, 22 11.03 M
Increased by +678.26%
-29.25 M
Increased by +24.73%
Decreased by -265.23%
Increased by +90.33%
Sep 30, 22 7.01 M
Increased by +482.46%
-41.42 M
Increased by +2.31%
Decreased by -591.14%
Increased by +83.23%
Jun 30, 22 5.54 M
Increased by +78.93%
-44.52 M
Decreased by -13.96%
Decreased by -803.90%
Increased by +36.31%
Mar 31, 22 3.58 M
Increased by +723.73%
-50.27 M
Decreased by -33.11%
Decreased by -1.41 K%
Increased by +83.84%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY